膜性肾病:量化缓解持续时间对结局的影响
该队列研究纳入376例经活检证实的特发性/原发性膜性肾病患者,均在肾病范围蛋白尿后达到缓解,在首次缓解后3、6、12、24、36个月固定时间点评估缓解状态,主要终点为终末期肾病或eGFR下降50%。持续缓解与主要终点风险降低相关,缓解持续时间越长肾脏生存改善越明显,但缓解仅3个月者预后仍优于复发者。
要点
- 持续缓解在3至36个月各时间点均与主要终点风险降低相关,校正后仍显著。
- 缓解持续时间越长,肾脏生存改善越明显;缓解仅3个月者预后仍优于复发者。
- 完全缓解与部分缓解分别分析结果相似,支持二者作为长期结局的替代指标。
核心结论
- 持续缓解与主要终点风险降低相关,缓解持续时间越长肾脏生存改善越明显。
- 缓解持续时间短至3个月的患者肾脏预后仍优于复发患者。
- 本研究验证并量化了部分缓解和完全缓解作为膜性肾病长期结局替代指标的价值。
研究设计与样本
- 队列研究,纳入376例经活检证实的特发性/原发性膜性肾病患者,均在肾病范围蛋白尿后达到缓解。
- 完全缓解定义为蛋白尿≤0.3 g/d,部分缓解定义为蛋白尿0.4-3.4 g/d,复发定义为完全或部分缓解后蛋白尿≥3.5 g/d。
- 暴露变量为首次缓解后3、6、12、24、36个月固定时间点的缓解状态,主要终点为终末期肾病或eGFR下降50%。
- 采用Cox比例风险模型分析各时间点缓解状态与主要终点的关联。
主要发现
- 持续缓解在各时间点与主要终点的未校正风险比范围为0.35(95%CI 0.20-0.61)至0.56(95%CI 0.31-1.04)。
- 部分缓解与完全缓解分别分析结果相似。
- 校正后,维持缓解在所有时间点均与主要终点风险显著降低相关。
- 缓解持续时间越长肾脏生存改善越明显,缓解仅3个月者肾脏预后仍优于复发者。
关键数值与推荐
- 完全缓解:蛋白尿≤0.3 g/d;部分缓解:蛋白尿0.4-3.4 g/d;复发:完全或部分缓解后蛋白尿≥3.5 g/d。
- 主要终点:终末期肾病或eGFR下降50%。
- 持续缓解与主要终点的未校正风险比范围:0.35(95%CI 0.20-0.61)至0.56(95%CI 0.31-1.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although change in proteinuria has been proposed as a surrogate for long-term prognosis in membranous nephropathy (MGN), variability in proteinuria levels and lag between these changes and acceptable end points, such as ESRD, has limited its utility. This cohort study examined the prognostic significance of remission duration in 376 patients with biopsy-proven idiopathic/primary MGN who achieved a remission after a period of nephrotic-range proteinuria. We defined complete remission (CR), partial remission (PR), and relapse as proteinuria ≤0.3, 0.4-3.4, and ≥3.5 g/d after CR or PR, respectively. The exposure variable was the remission status of patients at fixed landmarks (3, 6, 12, 24, and 36 months) after the date of first remission. The primary outcome was ESRD or 50% reduction in eGFR. We fitted Cox proportional hazards models to examine the association of remission status at each landmark and the primary end point. Persistent remission associated with unadjusted hazard ratios for the primary outcome that ranged by landmark from 0.35 (95% confidence interval, 0.20 to 0.61) to 0.56 (95% confidence interval, 0.31 to 1.04). Separate analyses for PR and CR yielded similar results. After adjustment, maintaining remission associated with significantly reduced risk of the primary outcome at all landmarks. Durable remissions associated with improved renal survival. Although the longer the remission, the greater the improvement, patients with remission durations as short as 3 months had improved renal prognosis compared with patients who relapsed. This study validates and quantifies PR and CR as surrogates for long-term outcome in MGN.
引用
- Cattran DC, Kim ED, Reich H, et al. Membranous Nephropathy: Quantifying Remission Duration on Outcome. J Am Soc Nephrol. 2016. PMID: 27756808. doi:10.1681/ASN.2015111262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。